American Century Companies’s Design Therapeutics DSGN Stock Holding History

American Century Companies's DSGN Position: Q2 2026 in Review

American Century Companies increased its Design Therapeutics (DSGN) stake by 17% in Q2 2026, buying an estimated $139K and bringing the position to 76,825 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

American Century Companies first reported a position in DSGN in Q2 2024 and has held it in 9 quarters since. 127 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

• American Century Companies held 76,825 shares of Design Therapeutics worth $1.11M as of Q2 2026.
• American Century Companies bought 11,187 Design Therapeutics shares in Q2 2026, an estimated $139K.
• Design Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2374 holding.
• American Century Companies first reported a position in Design Therapeutics in Q2 2024 and has held it in 9 quarters since.
• 127 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.